Compare UEIC & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | VERU |
|---|---|---|
| Founded | 1986 | 1971 |
| Country | United States | United States |
| Employees | 3838 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 39.8M |
| IPO Year | 1993 | 1990 |
| Metric | UEIC | VERU |
|---|---|---|
| Price | $3.59 | $2.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $9.25 | ★ $25.00 |
| AVG Volume (30 Days) | 81.8K | ★ 198.5K |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $390,997,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $2.69 | $2.10 |
| 52 Week High | $11.27 | $14.20 |
| Indicator | UEIC | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 35.09 |
| Support Level | $3.07 | $2.23 |
| Resistance Level | $3.15 | $2.42 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 98.36 | 8.21 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.